Literature DB >> 30029936

Indoleamine 2, 3-dioxygenase and B7-H1 expressions as prognostic and follow-up markers in human pancreatic carcinoma.

Liancai Wang1, Qingyong Ma2, Deyu Li3, Senmao Mu1, Yong Li1, Yafeng Wang1, Pengfei Shi1, Haibo Yu1, Chunhui Gao1, Kun Guo2, Zhuoli Zhang4.   

Abstract

This study was to test hypotheses that indoleamine 2, 3-dioxygenase and B7-H1 expressions can be used as prognostic markers in human pancreatic carcinoma (PC). Ninety-five patients were recruited who had undergone radical surgical resection for PC. IDO and B7-H1 expressions in PC tissue specimens were evaluated by immunohistochemistry (IHC) techniques. The clinical and pathological features of these specimens were analyzed. IDO positive, B7-H1 positive, and combined IDO/B7-H1 positive tumors exhibited significant correlations with lymphocytic infiltration, perineural invasion, TNM status, and pathologic grade (p < .05), which tended to show strong correlations with malignant progression of PC. Also, IDO correlated with diabetes mellitus (DM) and HAD scale and B7-H1 correlated with smoke (p < .05). In addition, the correlation analysis indicated that IDO had a positive correlation with B7-H1 (p < .05). Moreover, the results showed that a combination of IDO and B7-H1 expressions could serve as independent prognostic marker after adjusting by Cox proportional hazards regression models (p < .05). IDO and B7-H1 expressions were observed in patient with PC tissues and are important markers for PC malignant progression. A combination of IDO and B7-H1 expression can be served as an independent prognostic marker for PC.
Copyright © 2018. Published by Elsevier GmbH.

Entities:  

Keywords:  B7-H1; Human; IDO; Pancreatic carcinoma; Prognosis

Mesh:

Substances:

Year:  2018        PMID: 30029936     DOI: 10.1016/j.prp.2018.02.016

Source DB:  PubMed          Journal:  Pathol Res Pract        ISSN: 0344-0338            Impact factor:   3.250


  3 in total

1.  Programmed Cell Death Ligand-1 (PD-L1) and CD8 Expression Profiling Identify an Immunologic Subtype of Pancreatic Ductal Adenocarcinomas with Favorable Survival.

Authors:  Ludmila Danilova; Won Jin Ho; Qingfeng Zhu; Teena Vithayathil; Ana De Jesus-Acosta; Nilofer S Azad; Daniel A Laheru; Elana J Fertig; Robert Anders; Elizabeth M Jaffee; Mark Yarchoan
Journal:  Cancer Immunol Res       Date:  2019-05-01       Impact factor: 11.151

2.  Prognostic Value of Programmed Death Ligand-1 Expression in Solid Tumors Irrespective of Immunotherapy Exposure: A Systematic Review and Meta-Analysis.

Authors:  Ramy R Saleh; Jordan L Scott; Nicholas Meti; Danielle Perlon; Rouhi Fazelzad; Alberto Ocana; Eitan Amir
Journal:  Mol Diagn Ther       Date:  2022-02-01       Impact factor: 4.074

3.  Prognostic value of PD-L1 expression in patients with pancreatic cancer: A PRISMA-compliant meta-analysis.

Authors:  Ying Hu; Wanzhen Chen; Zhanpeng Yan; Jingxia Ma; Fangshi Zhu; Jiege Huo
Journal:  Medicine (Baltimore)       Date:  2019-01       Impact factor: 1.817

  3 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.